198 related articles for article (PubMed ID: 34976549)
1. Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial.
Cadegiani FA; Zimerman RA; Fonseca DN; Correia MN; Muller MP; Bet DL; Slaviero MR; Zardo I; Benites PR; Barros RN; Paulain RW; Onety DC; Israel KCP; Gustavo Wambier C; Goren A
Cureus; 2021 Dec; 13(12):e20691. PubMed ID: 34976549
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
4. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial.
McCoy J; Goren A; Cadegiani FA; Vaño-Galván S; Kovacevic M; Situm M; Shapiro J; Sinclair R; Tosti A; Stanimirovic A; Fonseca D; Dorner E; Onety DC; Zimerman RA; Wambier CG
Front Med (Lausanne); 2021; 8():668698. PubMed ID: 34350193
[TBL] [Abstract][Full Text] [Related]
5. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial.
Cadegiani FA; McCoy J; Gustavo Wambier C; Vaño-Galván S; Shapiro J; Tosti A; Zimerman RA; Goren A
Cureus; 2021 Feb; 13(2):e13492. PubMed ID: 33633920
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
[TBL] [Abstract][Full Text] [Related]
8. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients-a double-blind, placebo-controlled, clinical trial.
Srivastava A; Rengaraju M; Srivastava S; Narayanan V; Gupta V; Upadhayay R; Kumar J; Parameswaran S; KanakavalliKadarkarai ; AarthiVelmurugan
Trials; 2021 Aug; 22(1):570. PubMed ID: 34454572
[TBL] [Abstract][Full Text] [Related]
13. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical).
Cadegiani FA; McCoy J; Gustavo Wambier C; Goren A
Cureus; 2021 Feb; 13(2):e13047. PubMed ID: 33643746
[TBL] [Abstract][Full Text] [Related]
14. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.
Nickols NG; Mi Z; DeMatt E; Biswas K; Clise CE; Huggins JT; Maraka S; Ambrogini E; Mirsaeidi MS; Levin ER; Becker DJ; Makarov DV; Adorno Febles V; Belligund PM; Al-Ajam M; Muthiah MP; Montgomery RB; Robinson KW; Wong YN; Bedimo RJ; Villareal RC; Aguayo SM; Schoen MW; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Orshansky G; Norman LE; Tran S; Ghayouri L; Tsai S; Geelhoed M; Rettig MB
JAMA Netw Open; 2022 Apr; 5(4):e227852. PubMed ID: 35438754
[TBL] [Abstract][Full Text] [Related]
15. Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.
Qiao Y; Wotring JW; Zheng Y; Zhang CJ; Zhang Y; Jiang X; Pretto CD; Eyunni S; Parolia A; He T; Cheng C; Cao X; Wang R; Su F; Ellison SJ; Wang Y; Qin J; Yan H; Zhou Q; Ma L; Sexton JZ; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2023 Jul; 120(30):e2221809120. PubMed ID: 37459541
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
[TBL] [Abstract][Full Text] [Related]
17. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
[TBL] [Abstract][Full Text] [Related]
18. Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.
Busani S; Tosi M; Mighali P; Vandelli P; D'Amico R; Marietta M; Forfori F; Donati A; Cinnella G; De Monte A; Pasero D; Bellani G; Tascini C; Foti G; Ranieri M; Girardis M
Trials; 2020 Aug; 21(1):724. PubMed ID: 32807241
[TBL] [Abstract][Full Text] [Related]
19. Ivermectin for preventing and treating COVID-19.
Popp M; Reis S; Schießer S; Hausinger RI; Stegemann M; Metzendorf MI; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015017. PubMed ID: 35726131
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
